- Home
- IONS
as 02-21-2025 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.0B | IPO Year: | 1991 |
| Target Price: | $61.24 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.23 - $52.34 | Next Earning Date: | 02-19-2025 |
| Revenue: | $705,000,000 | Revenue Growth: | -10.49% |
| Revenue Growth (this year): | -19.91% | Revenue Growth (next year): | 10.08% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Monia Brett P | IONS | Chief Executive Officer | Feb 4 '25 | Sell | $31.65 | 38,843 | $1,229,462.52 | 180,683 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Feb 4 '25 | Sell | $31.62 | 6,165 | $194,939.15 | 57,452 | |
| Swayze Eric | IONS | EVP Research | Jan 30 '25 | Sell | $32.31 | 1,367 | $44,162.03 | 48,017 | |
| Monia Brett P | IONS | Chief Executive Officer | Jan 30 '25 | Sell | $32.45 | 13,242 | $429,655.23 | 180,683 | |
| Schneider Eugene | IONS | EVP, Chf Clinical Develop Ofcr | Jan 30 '25 | Sell | $32.20 | 1,484 | $47,779.90 | 61,056 | |
| BENNETT C FRANK | IONS | EVP, Chief Scientific Officer | Jan 30 '25 | Sell | $32.46 | 1,327 | $43,079.20 | 93,146 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Jan 30 '25 | Sell | $32.40 | 1,406 | $45,561.29 | 99,077 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Jan 30 '25 | Sell | $32.49 | 1,406 | $45,684.60 | 57,452 | |
| HOUGEN ELIZABETH L | IONS | EVP, Finance & CFO | Jan 30 '25 | Sell | $32.44 | 1,523 | $49,403.68 | 110,500 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Jan 15 '25 | Sell | $32.70 | 4,430 | $144,861.00 | 25,017 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James
Insider Monkey
2 days ago
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now
Zacks
2 days ago
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
Morningstar Research
2 days ago
Analyst Report: Ionis Pharmaceuticals, Inc.
Business Wire
2 days ago
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
Simply Wall St.
2 days ago
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
2 days ago
Q4 2024 Ionis Pharmaceuticals Inc Earnings Call
GuruFocus.com
2 days ago
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.